The Asia Pacific HIV Injection Market would witness market growth of 18.7% CAGR during the forecast period (2023-2030).
The China market dominated the Asia Pacific HIV Injection Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $172.7 Million by 2029. The Japan market is registering a CAGR of 17.9% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 19.4% during (2023 - 2030).
HIV injections are an important treatment option for people living with HIV, offering several advantages over oral medications, including improved adherence, reduced risk of drug interactions, and potentially higher efficacy. In recent years, the market has expanded substantially, propelled by the escalating the prevalence of HIV/AIDS and the rising need for efficacious treatment alternatives.
Injectable HIV medications offer several advantages over oral medications, including improved adherence, reduced pill burden, and potentially better long-term outcomes. As a result, the demand for injectable HIV medications has been steadily increasing, driving growth in the market. Regarding the management of HIV/AIDS, patient adherence and preference are critical, and injectable treatments contribute significantly to resolving these concerns.
The demand in the Asia Pacific is likely to be influenced by the high number of people living with HIV in the region, as well as the efforts of governments and organizations to expand access to HIV prevention, testing, treatment, and care. According to a report by the Organisation for Economic Co-operation and Development (OECD), Asia ranks second in the prevalence of individuals living with HIV, behind only sub-Saharan Africa. These factors will, consequently, bolster the development of the regional market.
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific HIV Injection Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $172.7 Million by 2029. The Japan market is registering a CAGR of 17.9% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 19.4% during (2023 - 2030).
HIV injections are an important treatment option for people living with HIV, offering several advantages over oral medications, including improved adherence, reduced risk of drug interactions, and potentially higher efficacy. In recent years, the market has expanded substantially, propelled by the escalating the prevalence of HIV/AIDS and the rising need for efficacious treatment alternatives.
Injectable HIV medications offer several advantages over oral medications, including improved adherence, reduced pill burden, and potentially better long-term outcomes. As a result, the demand for injectable HIV medications has been steadily increasing, driving growth in the market. Regarding the management of HIV/AIDS, patient adherence and preference are critical, and injectable treatments contribute significantly to resolving these concerns.
The demand in the Asia Pacific is likely to be influenced by the high number of people living with HIV in the region, as well as the efforts of governments and organizations to expand access to HIV prevention, testing, treatment, and care. According to a report by the Organisation for Economic Co-operation and Development (OECD), Asia ranks second in the prevalence of individuals living with HIV, behind only sub-Saharan Africa. These factors will, consequently, bolster the development of the regional market.
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F.Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Market Report Segmentation
By Distribution Channel- Hospital Pharmacy
- Drugs Stores & Retail Pharmacies
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific HIV Injection Market by Distribution Channel
Chapter 5. Asia Pacific HIV Injection Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F. Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Methodology
LOADING...
